Get In Touch

Healthcare Providers Increase Availability of Preventive & Curative Services During Coronavirus Pandemic

Healthcare utilization has repeatedly been observed to decrease during the ongoing COVID-19 pandemic. Such trends are affecting the growth of the solitary fibrous tumor treatment market. Many individuals still fear contracting the novel coronavirus infection. Hence, healthcare providers should increase the availability of preventive and curative services, especially for the most vulnerable populations such as older people, children, and for people living with chronic conditions.

Stakeholders in the solitary fibrous tumor treatment market are ensuring continuity of the delivery of essential healthcare services during the pandemic. They are taking efforts to adhere to government guidelines to reorganize and maintain safe access to essential health services. Pharmaceutical companies are maintaining optimum inventory levels to ensure robust supply of life-saving therapeutics.

solitary fibrous tumor treatment market infographic

To know the scope of our report Get a Sample on Solitary Fibrous Tumor Treatment Market

Lack of Evidence Base for Treatment Affecting Market Growth

The solitary fibrous tumor treatment market is expected to reach US$ 59.3 Mn by 2031. However, it has been found that there is no consensus guideline on the management of solitary fibrous tumors of the pleura (SFTP) and the evidence base for treatment is limited, resulting in large variations in care. Nevertheless, stakeholders are fueling their R&D efforts to increase the availability of treatments for solitary fibrous tumor (SFT).

Pazopanib holds promising potentials for advanced solitary fibrous tumor treatment. This multikinase inhibitor helps to address translocation-associated soft tissue sarcoma. Pazopanib therapy is being associated with radiological evidence of tumor response in many patients.

Get a glimpse of the in-depth analysis through our Report Brochure

Multi-disciplinary Approach Holds Promising Potentials in Increasing Patient Outcomes

In order to increase patient outcomes, companies in the solitary fibrous tumor treatment market are increasing their research in a multi-disciplinary approach. They are mainly focusing on the identification of the hallmark NAB2-STAT6 fusion that is emerging as a foundation for future translational work to identify subtype-specific therapy for the subset of SFTs that require systematic treatments.

Surgery remains the gold standard for increasing medical outcomes in the solitary fibrous tumor treatment market. On the other hand, antiangiogenic treatment is found to be effective for unresectable disease. There is a need for translational work to understand the biology driving the differential behavior of SFT and identify more effective treatments for patients with metastatic disease.

Adoption of Adjuvant Radiation Therapy Helps Control Subtotally-resected Pleural SFTs

The solitary fibrous tumor treatment market is projected to expand at a modest CAGR of 4.5% during the forecast period. Gross tumor resection remains the preferred choice for treatment of SFT. However, risk of blood loss, location, and adhesion might not always allow for this. This has led to the adoption of the adjuvant radiation therapy to achieve local control in subtotally-resected pleural SFTs.

The varying doses of external beam radiotherapy are being delivered to patients in order to improve clinical outcomes. Healthcare providers in the solitary fibrous tumor treatment market are gaining awareness that monitoring and surveillance of patients is important for better outcomes. As such, there is a need for further work on dedifferentiated SFT, which remains poorly understood.

solitary fibrous tumor treatment market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Since healthcare utilization has increased during the COVID-19 pandemic, telehealth services and mobile apps hold promising potentials to encourage individuals to seek treatment at professional healthcare facilities. Since SFT is a rare subtype of STS (Soft-tissue Sarcoma), stakeholders in the solitary fibrous tumor treatment market should adopt a multi-disciplinary approach to deliver optimal outcomes for patients. It has been found that antiangiogenics are active and their sequential use from first line should be considered, except for dedifferentiated SFT for which chemotherapy is an optimum option. Immunohistochemistry is known to be one of the most sensitive and specific means of diagnosing SFT and is practical & economical as well. 

Solitary Fibrous Tumor Treatment Market: Overview

  • Solitary fibrous tumor (SFT) is a very rare malignant condition that exhibits different clinical behaviors ranging from low to high aggressive SFT, with dedifferentiated SFT (DD-SFT) being the fastest-growing subtype
  • Solitary fibrous tumors can be classified by the site of origin: pleura, mediastinal, or pulmonary. The most common site of origin within the thorax is the pleura.

Solitary Fibrous Tumor Treatment: Market Drivers

  • Increase in patient awareness about personal health boosts the demand for early diagnosis of rare cancer. Patients are more aware and proactive about their health and are willing to seek physician’s advice at an early stage.
  • Increase in per capita disposable income is encouraging people to spend more on healthcare, which, in turn, propels the global solitary fibrous tumor treatment market
  • Awareness initiatives have increased public visibility of new treatments and diagnostic methods, thereby generating interest among solitary fibrous tumor patients

Market Segmentation: Solitary Fibrous Tumor Treatment Market

  • In terms of treatment, the global solitary fibrous tumor treatment market has been classified into surgery, radiation therapy, and adjuvant chemotherapy
  • Based on end-user, the global solitary fibrous tumor treatment market has been divided into hospitals, ambulatory surgical centers, and clinics
  • Each of the segments has been analyzed in detail for trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The solitary fibrous tumor treatment market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.

Regional Overview: Solitary Fibrous Tumor Treatment Market

  • The global solitary fibrous tumor treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • The U.S. held significant share of the solitary fibrous tumor treatment market in North America in 2020. The country is expected to retain market share during the forecast period. Robust healthcare infrastructure and early adoption of advanced treatment procedures can be attributed to the U.S.’s dominance of the solitary fibrous tumor treatment market in the region.
  • Asia Pacific is likely to gain market share during the forecast period. Product launches, acquisitions, distribution agreements, alliances, and geographical expansion by players, especially in China and India, are projected to drive the solitary fibrous tumor treatment market in the region.
  • Current and future market sizes in terms of value (US$ Mn) of these regional markets and major countries have been provided in the solitary fibrous tumor treatment market report for the period from 2017 to 2031, along with their CAGRs for the period from 2021 to 2031
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which are likely to help new companies willing to enter the solitary fibrous tumor treatment market and existing companies to increase market share and in the decision-making process

Major Players

  • The report concludes with the company profiles section that includes key information about the major players in the global solitary fibrous tumor treatment market
  • Leading players analyzed in the solitary fibrous tumor treatment market report are
    • Pfizer, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Eli Lilly and Company
    • Bayer AG
    • Novartis AG
  • Each of these players has been profiled in the solitary fibrous tumor treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Solitary Fibrous Tumor Treatment Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 36.5 Mn

Market Forecast Value in 2031

US$ 59.3 Mn

Growth Rate (CAGR)

4.5%

Forecast Period

2021–2031

Quantitative Units

US$ Mn for Value

Market Analysis

The report scope includes segment analysis of North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, qualitative analysis includes drivers, restraints, opportunities, key industry events, pipeline analysis, patient population data per year and COVID-19 impact analysis.

Competition Landscape

Company profiles section includes overview, business overview, strategy & recent developments, key financials, etc.

Format

Electronic (PDF) + Excel

Market Segmentation

  • Treatment
    • Surgery
    • Radiation Therapy
    • Adjuvant Chemotherapy
  • End-user
    • Hospitals
    • Ambulatory Surgical Centers
    • Others

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Pfizer, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Bayer AG
  • Novartis AG

Customization Scope

Available upon request

Pricing

Available upon request

Solitary Fibrous Tumor Treatment Market – Scope of Report

TMR’s report on the global solitary fibrous tumor treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides the revenue of the global solitary fibrous tumor treatment market for the period 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global solitary fibrous tumor treatment market from 2021 to 2031.

The report has been prepared after extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key industry leaders and opinion makers. Secondary research involved referring to key players’ literature, annual reports, press releases, and relevant documents to understand the global solitary fibrous tumor treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global solitary fibrous tumor treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Moreover, the report sheds light on changing competitive dynamics in the global solitary fibrous tumor treatment market. These serve as valuable tools for existing market players as well as entities interested in participating in the global solitary fibrous tumor treatment market.

The report also delves into the competitive landscape of the global solitary fibrous tumor treatment market. Key players operating in the global solitary fibrous tumor treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global solitary fibrous tumor treatment market that have been profiled in this report.

Key Questions Answered in Solitary Fibrous Tumor Treatment Market Report

  • What is the sales/revenue generated by treatment providers across all regions during the forecast period?
  • What are the opportunities in the global solitary fibrous tumor treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the global market?
  • Which region is set to expand at the fastest CAGR during the forecast period?
  • Which application segment is expected to generate the highest revenue globally in 2031?
  • What are the market positions of different companies operating in the global market?

Solitary Fibrous Tumor Treatment Market – Research Objectives and Research Approach

The comprehensive report on the global solitary fibrous tumor treatment market begins with an overview, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of treatments.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that have been appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global solitary fibrous tumor treatment market in terms of treatment, end-user, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders to make informed business decisions for investment in the global solitary fibrous tumor treatment market.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Solitary Fibrous Tumor Treatment Market – Segmentation

TMR’s study on the global solitary fibrous tumor treatment market includes information divided into three segments: treatment, end-user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global solitary fibrous tumor treatment market have been discussed in detail.

Treatment
  • Surgery
  • Radiation Therapy
  • Adjuvant Chemotherapy
End-user
  • Ambulatory Surgical Centers
  • Hospitals
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Solitary Fibrous Tumor Treatment Market

4. Market Overview

    4.1. Introduction & Overview

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunities

    4.3. Global Solitary Fibrous Tumor Treatment Market Analysis and Forecast, 2017–2031

5. Market Outlook

    5.1. Pipeline Analysis

    5.2. COVID-19 Impact Analysis

    5.3. Patients Population Data, 2018-2020

6. Global Solitary Fibrous Tumor Treatment Market Analysis and Forecast, by Treatment

    6.1. Introduction & Definition

    6.2. Global Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

        6.2.1. Surgery

        6.2.2. Radiation Therapy

        6.2.3. Adjuvant Chemotherapy

    6.3. Global Solitary Fibrous Tumor Treatment Market Attractiveness Analysis, by Treatment

7. Global Solitary Fibrous Tumor Treatment Market Analysis and Forecast, by End-user

    7.1. Introduction & Definition

    7.2. Global Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        7.2.1. Ambulatory Surgical Centers

        7.2.2. Hospitals

        7.2.3. Others

    7.3. Global Solitary Fibrous Tumor Treatment Market Attractiveness Analysis, by End-user

8. Global Solitary Fibrous Tumor Treatment Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Global Solitary Fibrous Tumor Market Value (US$ Mn) Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Global Solitary Fibrous Tumor Treatment Market Attractiveness Analysis, by Region

9. North America Solitary Fibrous Tumor Treatment Market Analysis and Forecast

    9.1. Introduction

    9.2. North America Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

        9.2.1. Surgery

        9.2.2. Radiation Therapy

        9.2.3. Adjuvant Chemotherapy

    9.3. North America Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        9.3.1. Ambulatory Surgical Centers

        9.3.2. Hospitals

        9.3.3. Others

    9.4. North America Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

        9.4.1. U.S.

        9.4.2. Canada

    9.5. North America Solitary Fibrous Tumor Market Attractiveness Analysis

        9.5.1. By Treatment

        9.5.2. By End-user

        9.5.3. By Country

10. Europe Solitary Fibrous Tumor Treatment Market Analysis and Forecast

    10.1. Introduction

    10.2. Europe Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

        10.2.1. Surgery

        10.2.2. Radiation Therapy

        10.2.3. Adjuvant Chemotherapy

    10.3. Europe Solitary Fibrous Tumor Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        10.3.1. Ambulatory Surgical Centers

        10.3.2. Hospitals

        10.3.3. Others

    10.4. Europe Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Europe Solitary Fibrous Tumor Treatment Market Attractiveness Analysis

        10.5.1. By Treatment

        10.5.2. By End-user

        10.5.3. By Country/Sub-region

11. Asia Pacific Solitary Fibrous Tumor Treatment Market Analysis and Forecast

    11.1. Introduction

    11.2. Asia Pacific Solitary Fibrous Tumor Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

        11.2.1. Surgery

        11.2.2. Radiation Therapy

        11.2.3. Adjuvant Chemotherapy

    11.3. Asia Pacific Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        11.3.1. Ambulatory Surgical Centers

        11.3.2. Hospitals

        11.3.3. Others

    11.4. Asia Pacific Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Asia Pacific Solitary Fibrous Tumor Market Attractiveness Analysis

        11.5.1. By Treatment

        11.5.2. By End-user

        11.5.3. By Country/Sub-region

12. Latin America Solitary Fibrous Tumor Treatment Market Analysis and Forecast

    12.1. Introduction

    12.2. Latin America Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

        12.2.1. Surgery

        12.2.2. Radiation Therapy

        12.2.3. Adjuvant Chemotherapy

    12.3. Latin America Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        12.3.1. Ambulatory Surgical Centers

        12.3.2. Hospitals

        12.3.3. Others

    12.4. Latin America Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Latin America Solitary Fibrous Tumor Market Attractiveness Analysis

        12.5.1. By Treatment

        12.5.2. By End-user

        12.5.3. By Country/Sub-region

13. Middle East & Africa Solitary Fibrous Tumor Treatment Market Analysis and Forecast

    13.1. Introduction

    13.2. Middle East & Africa Solitary Fibrous Tumor Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

        13.2.1. Surgery

        13.2.2. Radiation Therapy

        13.2.3. Adjuvant Chemotherapy

    13.3. Middle East & Africa Solitary Fibrous Tumor Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        13.3.1. Ambulatory Surgical Centers

        13.3.2. Hospitals

        13.3.3. Others

    13.4. Middle East & Africa Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Middle East & Africa Solitary Fibrous Tumor Market Attractiveness Analysis

        13.5.1. By Treatment

        13.5.2. By End-user

        13.5.3. By Country/Sub-region

        13.5.4. Competition Landscape

    13.6. Competition Landscape

    13.7. Company Profiles

        13.7.1. Pfizer, Inc.

            13.7.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.7.1.2. Growth Strategies

            13.7.1.3. SWOT Analysis

        13.7.2. F. Hoffmann-La Roche Ltd.

            13.7.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.7.2.2. Growth Strategies

            13.7.2.3. SWOT Analysis

        13.7.3. Eli Lilly and Company

            13.7.3.1. Company Overview (HQ, Business Segments)

            13.7.3.2. Growth Strategies

            13.7.3.3. SWOT Analysis

        13.7.4. Bayer AG

            13.7.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.7.4.2. Growth Strategies

            13.7.4.3. SWOT Analysis

        13.7.5. Novartis AG

            13.7.5.1. Company Overview (HQ, Business Segments)

            13.7.5.2. Growth Strategies

            13.7.5.3. SWOT Analysis

List of Tables

Table 01: Global Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 02: Global Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 03: Global Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 04: North America Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 05: North America Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 06: North America Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 07: Europe Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 08: Europe Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 09: Europe Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 10: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 11: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 12: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 13: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 15: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 16: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 18: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031

List of Figures

Figure 01: Global Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 02: Global Solitary Fibrous Tumor Treatment Market Value Share, by Region, 2020

Figure 03: Global Solitary Fibrous Tumor Treatment Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 04: Global Solitary Fibrous Tumor Treatment Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 05: Global Solitary Fibrous Tumor Treatment Market Revenue (US$ Mn), by Surgery, 2017–2031

Figure 06: Global Solitary Fibrous Tumor Treatment Market Revenue (US$ Mn), by Radiation Therapy, 2017–2031

Figure 07: Global Solitary Fibrous Tumor Treatment Market Revenue (US$ Mn), by Adjuvant Chemotherapy, 2017–2031

Figure 08: Global Solitary Fibrous Tumor Treatment Market Value Share Analysis, by End-user, 2020 and 2031

Figure 09: Global Solitary Fibrous Tumor Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Figure 10: Global Solitary Fibrous Tumor Treatment Market Revenue (US$ Mn), by Hospitals, 2017–2031

Figure 11: Global Solitary Fibrous Tumor Treatment Market Revenue (US$ Mn), by Ambulatory Surgery Centers, 2017–2031

Figure 12: Global Solitary Fibrous Tumor Treatment Market Revenue (US$ Mn), by Others, 2017–2031

Figure 13: Global Solitary Fibrous Tumor Treatment Market Value Share Analysis, by Region, 2020 and 2031

Figure 14: Global Solitary Fibrous Tumor Treatment Market Attractiveness Analysis, by Region, 2021–2031

Figure 15: North America Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 16: North America Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Country, 2020 and 2031

Figure 17: North America Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Country, 2021–2031

Figure 18: North America Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by End-user, 2020 and 2031

Figure 19: North America Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Figure 20: North America Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 21: North America Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 22: Europe Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 23: Europe Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 24: Europe Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 25: Europe Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by End-user, 2020 and 2031

Figure 26: Europe Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Figure 27: Europe Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 28: Europe Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 29: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 30: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 31: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 32: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by End-user, 2020 and 2031

Figure 33: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Figure 34: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 35: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 36: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 37: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 38: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 39: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 40: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 41: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by End-user, 2020 and 2031

Figure 42: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Figure 43: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 44: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 45: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 46: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 47: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 48: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by End-user, 2020 and 2031

Figure 49: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Solitary Fibrous Tumor Treatment Market